Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.62 |
| ▸ | ACE | P12821 | 3/20 | 0.62 |
| ▸ | CPA1 | P15085 | 2/20 | 0.62 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | TERT | O14746 | 1/20 | 0.49 |
| ▸ | ECE1 | P42892 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 4/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10338209 | 1.00 | MME (0.62) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL8728265 | 1.00 | MME (0.62) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL30052810 | 0.93 | MME (0.56) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL30051655 | 0.88 | MME (0.54) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL30051352 | 0.87 | MME (0.53) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL30051565 | 0.85 | MME (0.51) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL26255783 | 0.85 | TERT (0.49) | MMEACECPA1ACE2TERT | |
| SCHEMBL30455467 | 0.84 | MME (0.50) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL30053138 | 0.83 | MME (0.49) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL12259750 | 0.82 | TERT (0.46) | MMEACECPA1ACE2TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709912-A1 | PROTEIN THERAPEUTICS FOR TREATMENT OF SENESCENT CELLS | BioAtla, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| US-12285037-B2 | Flavor composition and edible compositions containing same | MARS, INCORPORATED (US) | 2025-04-29 | — | — | US | claimed |
| WO-2024232976-A1 | PROTEIN THERAPEUTICS FOR TREATMENT OF SENESCENT CELLS | BIOATLA, INC. (US) | 2024-11-14 | — | — | WO | claimed |
| EP-4424365-A2 | PET FOOD COMPOSITIONS | Hill's Pet Nutrition, Inc. (US) | 2024-09-04 | — | — | EP | claimed |
| US-20240287509-A1 | NANO COMPLEX FOR TARGETED REPAIRING OF NEUROVASCULAR LESION, AND PREPARATION AND USE THEREOF | SHANGHAI JIAOTONG UNIVERSITY SCHOOL OF MEDICINE (CN) | 2024-08-29 | — | — | US | claimed |
| EP-4017281-B1 | PET FOOD COMPOSITIONS | HILLS PET NUTRITION INC (US) | 2024-08-28 | — | — | EP | claimed |
| US-12050228-B2 | Automated sample quality assessment | METABOLON, INC. (US) | 2024-07-30 | — | — | US | claimed |
| US-20240199698-A1 | PEPTIDE AMPHIPHILE COMPOSITIONS AND METHODS OF USE THEREOF | Endomimetics LLC | 2024-06-20 | — | — | US | claimed |
| US-20240044046-A1 | PROTEIN THERAPEUTICS FOR TREATMENT OF SENESCENT CELLS | BIOATLA, INC. (US) | 2024-02-08 | — | — | US | claimed |
| US-11892458-B2 | Biochemical predictors of red blood cell quality | BLOODWORKS NW (US) | 2024-02-06 | — | — | US | claimed |
| US-11351264-B2 | PAR2 mimetic peptides and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2022-06-07 | — | — | US | claimed |
| CN-114269768-A | Peptide for improving memory and preventing or improving cognitive dysfunction, composition comprising the same, and preparation method thereof | 纳特恩斯株式会社 | 2022-04-01 | — | — | CN | claimed |
| WO-2021127701-A1 | PET FOOD COMPOSITIONS | HILL'S PET NUTRITION, INC. (US) | 2021-06-24 | — | — | WO | claimed |
| US-20210088539-A1 | AUTOMATED SAMPLE QUALITY ASSESSMENT | METABOLON, INC. | 2021-03-25 | — | — | US | claimed |
| US-20210055313-A1 | BIOCHEMICAL PREDICTORS OF RED BLOOD CELL QUALITY | BLOODWORKS (US) | 2021-02-25 | — | — | US | claimed |
| US-10890592-B2 | Automated sample quality assessment | METABOLON, INC. (US) | 2021-01-12 | — | — | US | claimed |
| US-10830777-B2 | Biochemical predictors of red blood cell quality | BLOODWORKS (US) | 2020-11-10 | — | — | US | claimed |
| EP-3565846-A1 | PROTEIN THERAPEUTICS FOR TREATMENT OF SENESCENT CELLS | Bioatla, LLC (US) | 2019-11-13 | — | — | EP | claimed |
| WO-2018129007-A1 | PROTEIN THERAPEUTICS FOR TREATMENT OF SENESCENT CELLS | BIOATLA LLC (US) | 2018-07-12 | — | — | WO | claimed |
| US-20170067884-A1 | Method for the Early Detection of Autism Spectrum Disorder by use of Metabolic Biomarkers | GREENWOOD GENETIC CENTER | 2017-03-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11351264-B2 | PAR2 mimetic peptides and uses thereof | F2RL1, F2R, F2RL3 | MME 166/4885ACE 710/4885CPA1 175/4885 |
| US-20240199698-A1 | PEPTIDE AMPHIPHILE COMPOSITIONS AND METHODS OF USE THEREOF | PLD4, NGLY1, VIP | MME 274/4885ACE 1225/4885CPA1 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.